Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

NCT00217542 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Recurrent Renal Cell Cancer
Stage III Melanoma
Stage IV Melanoma
Stage IV Renal Cell Cancer

Interventions

BIOLOGICAL: recombinant interferon alfa-2b
DRUG: amifostine/azacitidine

Sponsor

National Cancer Institute (NCI)